International Journal of Chronic Obstructive Pulmonary Disease最新文献

{"title":"Development of a Multivariable Predictive Model for Adherence to Remotely Monitored Home-Based Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease.","authors":"Sheng Ye, Zi Chen, Dandan Zhang, Tingting Xia, Caihua Wang, Biyun Xu, Qin Li, Cheng Wang, Ye Zhang, Zhifei Yin, Jinfan Wang","doi":"10.2147/COPD.S534600","DOIUrl":"https://doi.org/10.2147/COPD.S534600","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to explore factors affecting adherence to remote home-based pulmonary rehabilitation (PR) in patients with stable chronic obstructive pulmonary disease (COPD) and to develop a predictive model.</p><p><strong>Patients and methods: </strong>This multicenter, cross-sectional survey study included 86 patients who underwent 12 weeks of health education-integrated, home-based PR with remote monitoring. Patients were stratified into high-completion (HC, ≥ 70%) and low-completion (LC, < 70%) groups. Demographic data, clinical features, and psychological parameters were analyzed. Receiver operating characteristic curve and area under the curve (AUC) analyses evaluated the predictive performance of key indicators. Binary logistic regression identified four predictors: Pulmonary Rehabilitation Adapted Index of Self-Efficacy (PRAISE), Outcome Expectations for Exercise Scale (OEE), Montreal Cognitive Assessment (MoCA), and Visual Analog Scale (VAS). These components formed an optimized predictive model with corresponding formula and cutoff values.</p><p><strong>Results: </strong>A cross-sectional survey of 71 patients, 44 in the HC group and 27 in the LC group, revealed significantly higher scores in the HC group in the following domains of the 36-Item Short Form Health Survey (SF-36), including physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, mental health, and social functioning, as well as in the MoCA scores (all p-values < 0.05). Significant intergroup differences were also observed in PRAISE, OEE and VAS scores (all p < 0.001). PRAISE (AUC = 0.810), OEE (AUC = 0.784), MoCA (AUC = 0.719), and VAS (AUC = 0.801) demonstrated discriminatory power in assessing PR adherence. The combined predictive model achieved an AUC of 0.895 (95% confidence interval: 0.812-0.977, p < 0.05), with 77.8% sensitivity and 93.2% specificity.</p><p><strong>Conclusion: </strong>Social cognitive theory (SCT) originated from social learning theory. It explains human behavior through a triadic, dynamic, and reciprocal model. This model posits continuous interaction among an individual's behavior, cognitive factors, and environmental context. The four-variable predictive model, based on SCT, effectively evaluates adherence to home-based PR under remote monitoring in patients with COPD. Among the indicators in the four-variable model, PRAISE shows potential as a target for intervention to enhance PR completion rates.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"3361-3375"},"PeriodicalIF":3.1,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12514956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145281514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Red Cell Distribution Width-to-Albumin Ratio Predicts 1-Year Mortality in Patients with Chronic Obstructive Pulmonary Disease: Evidence From MIMIC-IV and NHANES.","authors":"Pengcheng Sheng, Wanqi Lei, Tanyun Cheng, Yaoting Deng, Yeshan Li, Zhaoyan Wu, Bangzhu Liu","doi":"10.2147/COPD.S543479","DOIUrl":"10.2147/COPD.S543479","url":null,"abstract":"<p><strong>Purpose: </strong>The red blood cell distribution width-to-albumin ratio (RAR) is an emerging biomarker that reflects systemic inflammation and nutritional status. However, its prognostic value in patients with chronic obstructive pulmonary disease (COPD) remains unclear. This study aimed to evaluate the predictive value of RAR for 1-year all-cause mortality in patients with COPD and to explore its clinical relevance.</p><p><strong>Patients and methods: </strong>We conducted a retrospective analysis using two independent cohorts: hospitalized COPD patients from the MIMIC-IV database (2008-2019, n = 2649) and community-dwelling individuals with COPD from the NHANES database (2003-2018, n = 2415). RAR levels were stratified into quartiles (Q1-Q4). Multivariable logistic regression models were used to examine the association between RAR and 1-year all-cause mortality. Generalized additive models (GAMs) assessed nonlinear relationships. Receiver operating characteristic (ROC) analysis evaluated the predictive performance of RAR compared with other markers such as NLR, PLR, and RDW.</p><p><strong>Results: </strong>Higher RAR levels were independently associated with an increased risk of 1-year all-cause mortality in patients with COPD. In the MIMIC-IV cohort, the highest quartile (Q4) had an OR of 7.90 (95% CI: 6.05-10.32; P < 0.001) compared to Q1. In the NHANES cohort, the OR for Q4 was 11.16 (95% CI: 4.42-28.18; P < 0.001). ROC analysis revealed that RAR achieved a higher area under the curve (AUC) (0.801 in MIMIC-IV and 0.787 in NHANES) than other markers, indicating superior discriminatory ability.</p><p><strong>Conclusion: </strong>RAR serves as an independent predictor of 1-year all-cause mortality in patients with COPD. By integrating indicators of systemic inflammation and nutritional status, RAR provides a reliable tool for clinical risk stratification.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"3351-3360"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497373/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145239689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Home Non-Invasive Ventilation in Patients with Severe COPD with Hypercapnic Respiratory Failure: Impact on Long-Term Survival, Exacerbations and Mortality Related Factors.","authors":"Xavier Pomares, Concepción Montón, Cristina Lalmolda, Berta Lloret, Manel Luján","doi":"10.2147/COPD.S524130","DOIUrl":"10.2147/COPD.S524130","url":null,"abstract":"<p><strong>Background: </strong>Non-invasive ventilation (NIV) improves outcomes in acute life-threatening hypercapnic respiratory failure due to exacerbations of COPD (ECOPD), but the benefits of long-term home NIV (LTH-NIV) for managing hypercapnic chronic respiratory failure (CRF) in COPD remain unclear.</p><p><strong>Purpose: </strong>1) To assess the long-term survival of severe COPD patients with hypercapnic CRF started on LTH-NIV and mortality related factors; 2) To evaluate the impact of LTH-NIV on ECOPD and hospital admissions at follow-up.</p><p><strong>Patients and methods: </strong>COPD patients who started LTH-NIV between January 2009 and December 2018 were included. Medical records and clinical outcomes were retrospectively reviewed.</p><p><strong>Results: </strong>Forty-four COPD patients (mean [SD] age 66.5 [10.4] years, 81.8% men) with severe airflow obstruction (mean [SD] FEV₁ 36 [16] % of predicted), hypercapnic CRF (mean [SD] PaCO₂ 60.8 [9.2] mmHg) and exacerbator phenotype (mean [IQR] moderate-severe ECOPD 3 [3] in previous year) were included. Median survival from LTH-NIV was 100.3 months. Survival at one, three and five years was 86.4%, 72.7% and 68.2%, respectively. In a multivariate Cox regression model, patients with a significantly increased risk of death were those with older age, lower absolute FVC, more hospitalisations and especially those adapted to LTH-NIV in the acute phase (HR 3.67 (IC 1.04-13), p<0.05). LTH-NIV allowed an estimated mean reduction in ECOPD of 39.7% (65.2% in hospitalisations) at 12 months and 57.4% (81% in hospitalisations) at 24 months.</p><p><strong>Conclusion: </strong>The survival rate of COPD patients with hypercapnic CRF on LTH-NIV is currently high (>50% at 5 years). Adaptation to LTH-NIV in the stable phase is the most important prognostic determinant and should be considered especially in patients with more hospitalisations and lower FVC values. Initiation of LTH-NIV reduces moderate to severe ECOPD at follow-up.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"3339-3349"},"PeriodicalIF":3.1,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12493872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"miR-335-5p Predicts Elevated Chronic Obstructive Pulmonary Disease (COPD) Susceptibility and Its Role in Human Bronchial Epithelial Cells Injury.","authors":"Yifeng Zheng, Zhi Wu, Li Lin","doi":"10.2147/COPD.S517725","DOIUrl":"10.2147/COPD.S517725","url":null,"abstract":"<p><strong>Purpose: </strong>Chronic obstructive pulmonary disease (COPD) suffers from high prevalence, disability and mortality rates and a heavy economic burden. miR-335-5p takes part in multiple respiratory diseases such as pulmonary fibrosis, whereas its study in COPD has not been reported. The aim of our research was to explore miR-335-5p in predicting elevated COPD susceptibility and in human bronchial epithelial cells injury.</p><p><strong>Patients and methods: </strong>qRT-PCR was performed to examine miR-335-5p levels in serum and cells. ROC curve and logistic regression analyses were utilized to evaluate the predictive capacity of miR-335-5p for COPD susceptibility. Pearson correlation was used to assess the association of miR-335-5p with TNF-α, IL-6, FEV1, and FEV1/FVC. Human bronchial epithelial cells were exposed to cigarette smoke extract (CSE) conditions to simulate cell injury. Cell proliferation, apoptosis, inflammatory response and oxidative stress-related factors were assayed by CCK8, flow cytometry and ELISA, respectively.</p><p><strong>Results: </strong>miR-335-5p is reduced on COPD patients. ROC curve recommended that miR-335-5p has high sensitivity (88.9%) and specificity (80.0%) to distinguish COPD from healthy individuals. Logistic regression showed that reduced miR-335-5p predicted elevated COPD susceptibility. Moreover, miR-335-5p was significantly negatively related to TNF-α and IL-6 and positively related to FEV1, and FEV1/FVC in COPD patients. Cellular experiments revealed that CSE treatment decreased miR-335-5p expression, repressed cell proliferation, facilitated apoptosis, raised TNF-α, IL-6, ROS, and MDA levels, and reduced SOD levels. miR-335-5p overexpression facilitated cell proliferation, suppressed apoptosis, diminished TNF-α, IL-6, ROS, and MDA levels, and elevated SOD levels, whereas knockdown of miR-335-5p reversed this trend.</p><p><strong>Conclusion: </strong>Downregulation of miR-335-5p increased COPD susceptibility and negatively correlated with inflammatory factors. Overexpression of miR-335-5p alleviated CSE-induced injury to human bronchial epithelial cells, which suggested that miR-335-5p may be a potential target for COPD treatment.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"3317-3326"},"PeriodicalIF":3.1,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparable Clinical Outcomes with Tiotropium/Olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with COPD and Blood Eosinophil Count ≤300 Cells/μL.","authors":"Sanjay Sethi, Brendan Clark, Erin K Buysman, Andrew Sargent, Lindsay G S Bengtson","doi":"10.2147/COPD.S534974","DOIUrl":"10.2147/COPD.S534974","url":null,"abstract":"<p><strong>Introduction: </strong>Assessment of blood eosinophil count (BEC) is recommended to guide the use of inhaled corticosteroids in chronic obstructive pulmonary disease (COPD), with BEC ≥300 cells/μL predictive of patients most likely to benefit.</p><p><strong>Objective: </strong>To compare outcomes between patients initiating dual bronchodilator therapy with tiotropium/olodaterol (TIO/OLO) versus triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) in patients with COPD and BEC ≤300 cells/μL.</p><p><strong>Methods: </strong>A retrospective cohort study using claims data from the Optum Research Database. Patients with COPD initiated on TIO/OLO or FF/UMEC/VI between 01 June 2015 and 30 November 2019, with a baseline BEC were included. TIO/OLO initiators were 1:1 propensity score matched with FF/UMEC/VI initiators. Time to first exacerbation and pneumonia diagnosis were assessed using Kaplan-Meier analysis. COPD exacerbations and COPD and/or pneumonia-related healthcare resource utilization (HRU) and cost outcomes were presented as population annualized averages.</p><p><strong>Results: </strong>The study population included 3867 individuals with a baseline BEC result. Among these, 3168 (81.9%) had BEC ≤300 cells/μL. After matching, 1098 matched pairs with BEC ≤300 cells/μL were retained. The follow-up annualized count of moderate/severe exacerbations was not significantly different between TIO/OLO and FF/UMEC/VI initiators (1.05 vs 0.99, p=0.535). Annualized counts of COPD and/or pneumonia-related HRU were not significantly different, except for emergency department visits, which were lower for TIO/OLO than FF/UMEC/VI (0.59 vs 0.83, p=0.018). Annualized COPD and/or pneumonia-related emergency department ($370 vs $538, p=0.034) and pharmacy costs ($4692 vs $6573, p<0.001) were lower for TIO/OLO versus FF/UMEC/VI initiators.</p><p><strong>Conclusion: </strong>Eight in ten patients with COPD who initiated FF/UMEC/VI had BEC ≤300 cells/μL. TIO/OLO and FF/UMEC/VI users with BEC ≤300 cells/μL experienced similar rates of COPD exacerbations. TIO/OLO initiators incurred lower pharmacy costs related to COPD and/or pneumonia than FF/UMEC/VI initiators. These results support treatment recommendations of reserving inhaled corticosteroids for frequent exacerbators and patients with elevated eosinophil counts.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"3327-3338"},"PeriodicalIF":3.1,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12478208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase 2a, Randomized Trial of Mitiperstat Versus Placebo in Patients with COPD at High Risk of Exacerbation (CRESCENDO).","authors":"Rod Hughes, Wayne Brailsford, João Ferreira, James D Chalmers, Maria G Belvisi, Janwillem W H Kocks, Pauline Masters, Paul Thomson, Dawid Łyżwa, Sanna Rosengren, Jason David Cooper, Richard E K Russell, Dinesh Saralaya","doi":"10.2147/COPD.S524775","DOIUrl":"10.2147/COPD.S524775","url":null,"abstract":"<p><strong>Objective: </strong>Neutrophilic inflammation, a key feature of chronic obstructive pulmonary disease (COPD), is associated with exacerbations and poor outcomes. Myeloperoxidase (MPO) is released from activated neutrophil granules. High or increasing MPO levels are associated with tissue damage, lung function decline and increased exacerbation risk in patients with COPD. We hypothesize that treatment with mitiperstat, a novel oral MPO inhibitor, may reduce lung oxidative stress, inflammation and exacerbations, thereby improving symptoms, lung function, and comorbidities in patients with COPD.</p><p><strong>Patients and methods: </strong>CRESCENDO is a partially decentralized, Phase 2a, randomized, 24-week, double-blind study evaluating the efficacy and safety of mitiperstat versus placebo in patients (40-80 years, inclusive) with COPD at high risk of exacerbation (based on a documented history of ≥1 moderate or severe acute COPD exacerbation, frequent productive cough, or severe airflow limitation [forced expiratory volume in 1 second <50% predicted]). Patients recruited from approximately 100 sites across 14 countries, from primary or secondary care and community-based facilities, will be randomized 1:1 to receive mitiperstat 5 mg or placebo orally, once daily. The primary endpoint is the time to first CompEx event, a novel composite endpoint reflecting disease worsening, including changes in symptoms, reliever use, lung function, treatment for exacerbation, or study dropout. The study period is planned to take between 18 and 30 weeks for each patient.</p><p><strong>Conclusion: </strong>CRESCENDO will assess efficacy and safety of mitiperstat using a novel, patient-centric trial design to enhance participant recruitment, partially via community-based facilities, helping to overcome restrictive trial designs and better reflect the real-world population with COPD, as well as reducing its environmental impact.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"3305-3315"},"PeriodicalIF":3.1,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic Burden of Uncontrolled COPD Under Triple Therapy: A Population-Based Study.","authors":"Nicolas Molinari, Nicolas Roche, Anne-Lise Vataire, Stanislas Perrier, Nicolas Pagès, Arnaud Panes, Aurélie Schmidt, Arnaud Bourdin, Laurence Watier","doi":"10.2147/COPD.S532553","DOIUrl":"10.2147/COPD.S532553","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to provide real-life data on COPD healthcare resource utilization (HCRU)-related costs in patients receiving triple therapy and to quantify the economic burden of uncontrolled COPD patients (ie, ≥1 severe or 2 moderate exacerbations within 12 months before inclusion and at least one exacerbation under treatment) versus controlled COPD patients and the general population.</p><p><strong>Methods: </strong>Patients aged over 40 years receiving triple therapy in 2015 (ie, long-acting ß2-agonist, long-acting anticholinergic and inhaled corticosteroids) for at least 90 continuous days were included. The index date was defined as the 91st day of triple therapy exposure. Patients were followed for up to 5 years. HCRU-costs were computed by calendar year in controlled and uncontrolled COPD patients and in the general population. The association between costs and COPD has been estimated, for each calendar year, using GEE with a negative binomial distribution.</p><p><strong>Results: </strong>Among the 186,963 patients included, 21.2% (N= 39,647) of patients were identified as uncontrolled. Among these, the average cost related to HCRU per patient was around 12,000€ by year. Hospitalizations, drugs and medical devices represented approximately 2/3 of expenses. Costs were in average 1.25 higher than in controlled COPD treated patients and 2.7 higher than the general population. Attributable costs to COPD in uncontrolled patients were estimated at approximately €7,600 per patient each year.</p><p><strong>Conclusion: </strong>This study offers a robust representation of health care resource consumption and related costs of COPD patients receiving triple therapy in France over several years with a focus on uncontrolled patients.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"3295-3304"},"PeriodicalIF":3.1,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145193587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteome Profiling of Red Blood Cells from Patients with COPD Links Proteasome Activation with Abnormal Cell Morphology and Function.","authors":"Xi-Long Wang, Kai Zhong, Rui Li, Lin-Hui Huang, Guan-Jin Chen, Jin-Wei Chai, Xin Chen","doi":"10.2147/COPD.S531220","DOIUrl":"10.2147/COPD.S531220","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow obstruction and persistent respiratory symptoms. Molecular and cellular changes identified in red blood cells (RBCs) of COPD patients may contribute to the pathophysiology of COPD, impacting oxygen transport and systemic inflammation.</p><p><strong>Methods: </strong>We performed a comparative proteomic analysis on RBCs from 15 male COPD patients and 15 age- and sex-matched control subjects. For the proteomic analysis, individual samples were randomly pooled into 3 biological replicates per group (n = 3). Total RBC proteins were analyzed using tandem mass tag (TMT) labeling followed by LC-MS/MS. Differentially abundant proteins (DAPs) were identified and subjected to Gene Ontology (GO), KEGG pathway, and protein-protein interaction (PPI) network analyses.</p><p><strong>Results: </strong>We identified 160 DAPs (70 up-regulated, 90 down-regulated) in the RBCs of COPD patients. GO analysis revealed enrichment in processes related to protein stability regulation and immune response. KEGG pathway analysis showed that up-regulated proteins were most significantly enriched in the proteasome pathway, while down-regulated proteins were enriched in complement and coagulation cascades. Notably, a PPI network analysis highlighted a core complex of 10 up-regulated proteins that are all components of the proteasome regulatory particle.</p><p><strong>Conclusion: </strong>This study provides the in-depth RBC protein profile in COPD, identifying proteasome activation as a key molecular signature. These findings reveal novel biomarkers linked to RBC dysfunction that may contribute to the systemic pathology of COPD and offer potential new therapeutic targets.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"3279-3294"},"PeriodicalIF":3.1,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12466568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Obstructive Pulmonary Disease and Lung Cancer: A Meta-Analysis of Risk Association.","authors":"Peizuo Qiao, Ping Sheng, Hongxiang Liu, Hui Liang","doi":"10.2147/COPD.S539213","DOIUrl":"10.2147/COPD.S539213","url":null,"abstract":"<p><strong>Objective: </strong>Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by persistent respiratory symptoms and airflow limitation, which may involve mechanisms that are also implicated in lung carcinogenesis. This meta-analysis aimed to evaluate the association between COPD and the risk of developing lung cancer.</p><p><strong>Methods: </strong>A systematic literature search was conducted from database inception to March 20, 2022 across PubMed, Embase, Web of Science, and the Cochrane Library. Studies were independently screened by two reviewers, and relative risks (RRs) with 95% confidence intervals (CIs) were extracted and synthesized.</p><p><strong>Results: </strong>Nine studies were included in the final meta-analysis. A significantly increased risk of lung cancer was observed among individuals with COPD, with a pooled relative risk (RR) of 3.79 and a 95% confidence interval (CI) ranging from 3.60 to 3.98. Among individuals with COPD who did not use inhaled corticosteroids (ICS), the relative risk of lung cancer was 1.26 (95% CI: 1.20-1.33). The relative risk for females was 1.02 (95% CI: 0.99-1.05), suggesting no statistically significant difference in lung cancer risk by gender. The meta-analysis identified a moderate but statistically significant association between COPD and an increased risk of lung cancer.</p><p><strong>Conclusion: </strong>The results of this study are consistent with those of previous studies, further verifying that patients with COPD have a higher risk of lung cancer and providing stronger support for this finding. These findings underscore the need for enhanced surveillance and tailored preventive strategies among individuals diagnosed with COPD. Moving beyond traditional research paradigms to more refined, multidimensional approaches may improve the understanding of the link between COPD and lung cancer.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"3269-3277"},"PeriodicalIF":3.1,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12459382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145151440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fear of Falling in Patients with Chronic Obstructive Pulmonary Disease: Clinical Associations and Functional Impact.","authors":"Senay Demir Yazici, Onur Yazici","doi":"10.2147/COPD.S540279","DOIUrl":"10.2147/COPD.S540279","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to determine the frequency of fear of falling (FOF) in individuals with chronic obstructive pulmonary disease (COPD) and to evaluate its relationship with demographic, clinical, and functional parameters.</p><p><strong>Material and methods: </strong>Eighty COPD patients followed in a university hospital between May 2021 and December 2022 were included in this cross-sectional study. Perceived fear of falling was assessed with the Falls Efficacy Scale (FES), and functional balance was evaluated using the Berg Balance Scale (BBS). Physical performance was measured using the Timed Up and Go (TUG) test and Six-Minute Walk Test (6MWT). Symptoms were assessed with the COPD Assessment Test (CAT) and modified Medical Research Council Dyspnea Scale (mMRC). Respiratory function was measured using spirometric parameters including Forced Expiratory Volume in 1 second (FEV₁), Forced Vital Capacity (FVC), and the FEV₁/FVC ratio. Data analysis was conducted using SPSS.</p><p><strong>Results: </strong>The mean age of participants was 64.98±8.13 years, and 91.25% were male. FES scores were significantly higher in patients with fall history (45 [64-73] vs 20 [12-32], p<0.001). FOF was also significantly higher in those with comorbidities, especially hypertension (p=0.024) and heart failure (p=0.036). FOF differed across COPD groups, with Group E patients showing significantly higher FES scores than Groups A and B (59 [28-71.5] vs 16 [10-25] and 29 [14-45], respectively; p<0.001). Based on FEV₁, patients in Stages 3 and 4 had higher FOF than those in Stages 1 and 2 (p<0.05). FES scores positively correlated with age, COPD duration, CAT, mMRC, and TUG; and negatively with FEV₁, FVC, BBS, and 6MWT. All 10 patients with FES ≥70 had moderate fall risk by BBS. Among those with FES ≤70, 22.8% had moderate to high objective fall risk.</p><p><strong>Conclusion: </strong>FOF in COPD is associated with age, disease duration, symptom severity, balance, and physical capacity. Balance-focused interventions should be integrated into pulmonary rehabilitation.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"3241-3253"},"PeriodicalIF":3.1,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12459387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145151476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}